Correlation between c282y mutation of (hfe) gene with high sensitive troponin i in patients of ischemic heart diseases
Keywords:
IHD, C282Y, lipid profile, T2M, hs-troponin IAbstract
Objective Ischemic heart diseases are the most screen prevalence disease in the world and also diabetic mellitus increases all over the world, both have related to atherogenic lipoprotein modifications. Found the most common C282Y mutation of high ferritin (HFE) gene-related myocardial infarction and unstable angina. The aim of the presented work is to determine whether or not the C282Y mutation in the HFE gene might be correlated with the increased levels of hs-troponin I like a risk index of ischemic heart diseases in diabetic obese patients.
Methods A total of 100 individuals were used in this study, which were divided into (ischemic heart disease, diabetic and obese) and control (diabetic and obese) groups. Conducted in the cardiac care unit at Al-Zahra Teaching Hospital / Karbala and Najaf center for heart diseases between Nov. 2015 to Nov. 2016, after genomic DNA of blood extracted, the HFE gene mutation was detected using the PCR–RFLP technique, hs-troponin I, was determined by ELAIS technique.
Results The data analysis revealed a significant allele frequency of C282Y mutation among the case groups and controls (P < 0.05). The relationships between the GA and GG genotypes in C282Y mutation in hs-troponin I show a significant difference between the two groups (P = 0.002), lipid profile (TC, TG, LDL-C, HDL-C), Blood Pressure, Body Mass Index (BMI), didn’t show a significant difference between the two groups (P > 0.05). Lipid profile and BMI level were significant difference with independent predictors of IHD (P < 0.05).
Conclusion The results revealed a significant correlation between C282Y mutation and development of IHD in obese T2D patients with increasing levels of hs-troponin I.
References
2. Xie XX, Zhou WM, Lin F, Li XQ, Zhong WL, Lin SG, et al. Ischemic heart disease deaths, disability-adjusted life years and risk factors in Fujian, China during 1990–2013: Data from the Global Burden of Disease Study 2013. Int J Cardiol. 2016;214:265–269.
3. Elosua R, LluÃs-Ganella C, Subirana I, Havulinna A, Läll K, Lucas G, et al. Cardiovascular Risk Factors and Ischemic Heart DiseaseCLINICAL PERSPECTIVE. Circulation: Cardiovascular Genetics. 2016;9:279–286.
4. Leo P, Helge Boman, Stephen P. Daiger, Arno G. Motulsky. Familial aggregation of coronary heart disease and its relation to known genetic risk factors. Am J Cardiol. 1999;50:945–953.
5. Saremi L, Marzieh S, Shirin L, Saber I, Junjiang F, Tianyu Z. Correlation between HFE gene polymorphisms and increased risk of coronary artery disease among patients with type 2 diabetes in Iran. Turkish J Med Sci. 2016;46:590–596.
6. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et. al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis Nat Genet. 1996;13:399–408.
7. Bhatt L, Murphy C, O’Driscoll LS, Carmo-Fonseca M, McCaffrey MW, Fleming JV. N-glycosylation is important for the correct intracellular localization of HFE and its ability to decrease cell surface transferrin binding. FEBS J. 2010;277:3219–3234.
8. Shahzadi A, Sonmez I, Allahverdiyev O, Onal B, Kandaz C, Ozyazgan SO, et al. Cardiac troponin-I (cTnI) a biomarker of cardiac injuries induced by doxorubicin alone and in combination with ciprofloxacin, following acute and chronic dose protocol in Sprague Dawley rats. Int J Pharmacol. 2014;10:258–266.
9. Antman, Elliott M. Decision making with cardiac troponin tests. Expert opinion on pharmacotheropathy. 2012;1;8:2079–2082.
10. Apple FS, Collinson PO; IFCC Task force on clinical applications of cardiac biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. 2012;58:54–61.
11. Lian J, Limin X, Yi H, Yanping L, Danjie J, Xi Y, et al. Meta-analyses of HFE variants in coronary heart disease. Gene 2013;527:167–173.
12. Toraman, Ahmet Ruhi, Ahmet Gürel, Zeynep Ulusal, Gülnihal Bülbül, Ayşe Gülçin Demirdöven, Melek Uzun, Ali Özcan, and Muzaffer Cakmak. EvaEvaluation of glucose challenge and oral glucose tolerance test results in pregnancy and estimation of prevalence of gestational diabetes mellitus at Sema Hospital in İstanbul. Turkish J Med Sci. 2012;42:1235–1240.
13. Pardo Silva MC, Njajou OT, Alizadeh BZ, Hofman A, Witteman JC, van Duijn CM, et al. HFE gene mutations increase the risk of coronary heart disease in women. Eur J Epidemiol. 2010;25:643–649.
14. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary. Nat Genet. 1996;13:399–408.
15. Aguilar-Martinez P, Grandchamp B, Cunat S, Cadet E, Blanc F, Nourrit M, et al. Iron overload in HFE C282Y heterozygotes at first genetic testing: a strategy for identifying rare HFE variants. Haematologica. 2011;96:507–514.
16. Sayed AA, Aldebasi Y, Abd-allah SO, El, Gendy SM, Mohamed AS, Abd El-Fattah MS. Molecular and biochemical study of superoxide dismutase gene polymorphisms in egyptian patients with type 2 diabetes mellitus with and without retinopathy. Br J Med Med Res. 2013;3:1258.
17. Al-Tu’ma FJ, Abd-Yaser ZA, Al-Naffi KO. Association between hs-CRP levels and the severity of coronary atherosclerosis. J Contemp Med Sci. 2016;2:42–44.
18. Al-Tu’ma FJ, Abd-Yasera ZA, Al-Naffi KO. Role of Apo-lipoprotein A1 as cardiac biomarker for severity of coronary atherosclerosis. J Contemp Med Sci. 2015;1:27–30.
19. Al-Tu’ma FJ, Mahdi ZA, Abo Almaali HM. Relationship between serine/threonine kinase 39 gene polymorphisms with some cardiac biomarkers in hypertensive patients. J Contemp Med Sci. 2015;1:1–6.
20. Al-Tu’ma FJ, Al-Zubaidi RD, Al-Khaleeli AMB, Hassan M. Abo-Almaali. Polymorphism of tumor suppressor gene (p53) Codon 72 in Iraqi patients with acute myocardial infarction. J Contemp Med Sci. 2016;2:74–76.
21. Matheus AS, Tannus LR, Cobas RA, Palma CC, Negrato CA, Gomes MB. Impact of Diabetes on Cardiovascular Disease: An Update. Int J Hypertension. 2013:653789.